Shire plc has submitted regulatory filings with the EMA and FDA for the production of VPRIV (velaglucerase alfa) at its manufacturing facility in Lexington, MA. Subject to regulatory approval, the company expects the new plant to significantly increase manufacturing capacity and allow for increased global supply of VPRIV. These approvals would also allow for increased capacity for the manufacture of Replagal (agalsidase alfa) at Shire’s Alewife facility, where both VPRIV and Replagal are c...